BRONKAID MIST (epinephrine) by Knight Therapeutics is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. First approved in 1969.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
BRONKAID MIST is a metered-dose inhaled epinephrine aerosol approved in 1969 for acute bronchospasm and asthma symptoms. Epinephrine acts as a sympathomimetic amine, stimulating alpha and beta-adrenergic receptors to relax bronchial smooth muscle and improve airway patency. The product represents a legacy, over-the-counter bronchodilator for episodic respiratory distress.
Legacy product in final lifecycle stages with minimal growth opportunity; teams are typically small and focused on protecting market share against generic/OTC alternatives.
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Worked on BRONKAID MIST at Knight Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moBRONKAID MIST offers limited career growth due to zero linked job openings and approaching loss-of-exclusivity dynamics. Roles are primarily defensive, focused on protecting OTC market share and managing regulatory compliance in a declining therapeutic segment rather than driving innovation or expansion.